Innovo Therapeutics
AI-driven small-molecule immunology (private, pre-IPO)
Privately held: no public share price · South Korea
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Immune-cell energy metabolismSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.